Tech Company Financing Transactions

ReCode Therapeutics Funding Round

On 10/23/2021, ReCode Therapeutics landed $80 million in Series B investment from EcoR1 Capital Management, Pfizer Venture Investments and Colt Ventures.

Transaction Overview

Company Name
ReCode Therapeutics
Announced On
10/23/2021
Transaction Type
Venture Equity
Amount
$80,000,000
Round
Series B
Investors

EcoR1 Capital Management (Lead Investor) (Oleg Nodelman)

Pfizer Venture Investments (Lead Investor) (Rana Al-Hallaq)

Colt Ventures

Hunt Technology Ventures

MPM Capital (Ed Hurwitz)

NS Investment

OrbiMed (Peter Thompson)

Osage Partners

Sanofi-Genzyme BioVentures

Superstring Capital

Vida Ventures (Helen Kim)

Proceeds Purpose
The proceeds from the Series B financing will be used to drive ReCode's lead programs in primary ciliary dyskinesia (PCD) and cystic fibrosis (CF) into human clinical studies, expand the pipeline of treatments for patients with life-limiting genetic respiratory diseases, advance its LNP platform for organ-specific delivery of RNA and gene correction therapies and increase internal manufacturing capabilities.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1455 Adams Dr.
Menlo Park, CA 94025
USA
Phone
469-306-1618
Website
www.recodetx.com
Email Address
[email protected]
Overview
ReCode Therapeutics is a biopharmaceutical company developing precision medicines for pulmonary diseases with significant unmet medical need. ReCode's diverse pipeline includes lead programs for primary ciliary dyskinesia (PCD) and nonsense mutations in cystic fibrosis (CF).
Profile
ReCode Therapeutics LinkedIn Company Profile
Social Media
ReCode Therapeutics Company Twitter Account
Company News
ReCode Therapeutics News
Facebook
ReCode Therapeutics on Facebook
YouTube
ReCode Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
David Lockhart
  David Lockhart LinkedIn Profile  David Lockhart Twitter Account  David Lockhart News  David Lockhart on Facebook

 

 

Browse more venture capital transactions:

Prev: 10/23/2021: HT Aero venture capital transaction
Next: 10/23/2021: MagniLearn venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to report on all VC transactions involving tech companies. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.